Midgard Science

LIDE Biotech

lidebiotech.com From their website, Nov 2026

  • AAALAC

Work here? Claim this listing

About

LIDE Biotech is an oncology-focused preclinical CRO serving drug developers and research partners. It operates China-based labs with US and Europe-based leadership to support preclinical oncology, immuno-oncology, and related translational studies.

Services

  • Preclinical oncology studies

    Runs preclinical studies for oncology drug R&D across in-vivo and in-vitro model systems.

  • Immuno-oncology platform

    Provides syngeneic, humanized, IO-FIVE, and co-culture models and assays for immunotherapy development.

  • Drug resistant cancer models

    Offers patient-derived models and studies focused on drug-resistant cancers.

  • ADC development support

    Supports antibody-drug conjugate development with preclinical models and assays.

  • Patient-derived xenograft (PDX) models

    Provides a large library of patient-derived xenograft models for model search and study use.

  • Cell line-derived xenograft (CDX) models

    Provides ready-to-use CDX models for early in-vivo screening.

  • Orthotopic models

    Builds orthotopic models from PDX or CDX tissue for solid and liquid cancers.

  • Syngeneic models

    Offers immunocompetent murine tumor models for proof-of-concept and mechanism-of-action studies.

12 more services
  • Humanized models
  • Ex vivo models
  • 3D spheroid and organoid assays
  • CR cells
  • Co-culture assays for IO
  • Multi-omics analysis
  • Transcription analysis and bioinformatics
  • Sequencing
  • Functional genomic imaging (FGI)
  • Multiplex tissue imaging
  • Academic collaborations
  • Buying models
Turnaround
  • 7-10 days
  • As little as 14 days
What to send
  • Work email
  • Study needs
  • Near-term deadlines

Capabilities

Assays and studies
  • ADCs
  • Antibodies
  • Cell therapy
  • In-vivo efficacy studies
  • Mechanism-of-action studies
  • Proof-of-concept studies
5 more
  • Functional immune profiling
  • Biomarker discovery
  • High-throughput pre-validation
  • Compound screens
  • Efficacy studies
Scale and capacity
  • 2300+ PDX models
  • 120 CDX models
  • 225 frozen PDXO models across 21 cancer types
Therapeutic areas
  • Oncology
  • Immuno-oncology
  • Hematological malignancies
  • Blood cancers
  • Drug-resistant cancers

Instruments and platforms

  • MiniPDX
  • IO-FIVE
  • OncoVee™ K-Cell 1000 Cell Kit
  • Functional genomic imaging (FGI)

Modalities and species

Modalities
  • Antibody
  • Bispecific
  • ADC
  • Cell therapy
Species and models
  • Murine tumor models
  • huPBMC-reconstituted humanized models
  • CD34+ HSC humanized models
  • Humanized syngeneic models
  • Innate immune cell–involved systems
  • Macrophage
9 more
  • Dendritic cell
  • Patient-derived xenografts
  • Cell line-derived xenografts
  • Organoids
  • 3D spheroids
  • CR cells
  • PBMC humanized models
  • T/NK
  • CAR-T

Certifications

As the company states them, with the certificate or registry record where there is one.

  • AAALACSelf-reported

    Scope: labs

  • CAPSelf-reported

Details

Type
CRO
Founded
2011
Sites
  • Shanghai, China
  • San Francisco, USA
  • Philadelphia, USA
  • Nottingham, UK
Serves
Global, North America, Europe, APAC

Similar labs